{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:27:20Z","timestamp":1698733640942},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Management of patients with severe haemophilia A who develop inhibitors is difficult and expensive. Standard treatment of this complication is immune tolerance induction (ITI) therapy, but is successful in only 60\u201380% of the patients. Failure of ITI results in a higher risk of morbidity and mortality. We used rituximab, an anti\u2010CD20 antibody, in three patients with severe haemophilia A and inhibitors. Two patients with high\u2010titre inhibitors had marked reduction in the inhibitor level; the third patient with low\u2010titre inhibitor had a disappearance of the inhibitor. All patients improved clinically, with fewer bleeding episodes and a better quality of life. Inhibitor level increased with time in these patients, but the clinical benefit continued in two patients with high\u2010titre inhibitors initially, after a follow\u2010up of 48 and 22\u2003months. One of the patients with concomitant human immunodeficiency virus (HIV) infection and a very low CD4 lymphocyte count developed severe truncal herpes zoster after the third weekly dose of rituximab. Caution is required in such patients, and we recommend avoiding rituximab use in HIV\u2010infected patients with very low CD4 lymphocyte count. In conclusion, rituximab is useful in reducing the inhibitor level with clinical benefit in patients with severe haemophilia A and inhibitors, but it cannot eradicate the inhibitors for long periods with the currently used protocol of up to five doses.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01865.x","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T19:20:42Z","timestamp":1223493642000},"page":"210-216","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor"],"prefix":"10.1111","volume":"15","author":[{"given":"A.","family":"ALEEM","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"SAIDU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"ABDULKARIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"AL\u2010DIAB","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"AL\u2010SAGHEER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"QAYUM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"AL\u2010MOMEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/s-0037-1615061","article-title":"Factor VIII inhibitors in mild and moderate severity haemophilia A. UK Haemophilia Centre Directors Organisation","volume":"79","author":"Hay CR","year":"1998","journal-title":"J Thromb Haemost"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00379.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00950.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00781.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200405001-00005"},{"key":"e_1_2_5_9_2","first-page":"1186","article-title":"Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani G","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0038-1648828","article-title":"Immune tolerance in haemophilia\u2010principal results from the International Registry. Report of the Factor VIII and IX Subcommittee","volume":"72","author":"Mariani G","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00783.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood.V96.5.1698","article-title":"Immune tolerance induction in haemophiliac patients with inhibitors: costly can be cheaper","volume":"96","author":"Colowick AB","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_13_2","first-page":"558","article-title":"Immune tolerance induction with recombinant factor VIII in haemophilia A patients with high responding inhibitors","volume":"91","author":"Rocino A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01170.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01407.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04916.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666060-00005"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00196.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0392"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3547"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10541"},{"key":"e_1_2_5_22_2","first-page":"2109","article-title":"Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti\u2010tumor necrosis factor\u2010alpha treatment","volume":"32","author":"Higashida J","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH06-06-0317","article-title":"The efficacy of rituximab in the treatment of inhibitor\u2010associated hemostatic disorders","volume":"96","author":"Franchini M","year":"2006","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01342.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01185.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612589"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01215.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01351.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01654.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01212.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06311.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01372.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167660.30886.e9"},{"issue":"1","key":"e_1_2_5_34_2","article-title":"Immune tolerance induction with highly purified plasma\u2010derived factor VIII containing von Willibrand factor in haemophilia A patients with high\u2010responding inhibitors","volume":"3","author":"Orsini F","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01865.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01865.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:10:22Z","timestamp":1697364622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01865.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01865.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01865.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}